Statements (134)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:virus
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:HIV-2
gptkb:hepatitis_B_virus gptkb:Tibotec |
| gptkbp:advises |
focus on elimination by 2030
|
| gptkbp:affects |
can include chronic fatigue
can include liver damage |
| gptkbp:caused_by |
gptkb:healthcare_organization
|
| gptkbp:clinical_trial |
ongoing for new treatments
ongoing for new therapies exist in treatment access and outcomes |
| gptkbp:code |
gptkb:battle
|
| gptkbp:community_support |
can aid in recovery and management
|
| gptkbp:complications |
often present with other diseases
|
| gptkbp:cultural_practices |
associated with drug use
|
| gptkbp:current_use |
liver disease
extrahepatic manifestations |
| gptkbp:data_usage |
higher in certain populations
|
| gptkbp:diplomatic_relations |
impact access to treatment
|
| gptkbp:discovered_by |
discovered in 1989
|
| gptkbp:duration |
8 to 12 weeks
|
| gptkbp:education |
important for management
crucial for management important for understanding the disease |
| gptkbp:film_score |
used to evaluate liver health
|
| gptkbp:genetic_diversity |
varies by region
six genotypes more common in the Middle East most common genotype in the US six main genotypes high among different genotypes more common in Southeast Asia associated with liver disease less common genotype more common in South Africa |
| gptkbp:global_presence |
significant public health issue
|
| gptkbp:goal |
eliminate HCV by 2030
|
| gptkbp:grooming_needs |
monitored during treatment
|
| gptkbp:healthcare |
varies by country
aim to reduce transmission screening recommended for high-risk groups significant global health issue can be high due to chronic management important for ongoing care |
| https://www.w3.org/2000/01/rdf-schema#label |
HCV
|
| gptkbp:is_a_resource_for |
available for support and information
|
| gptkbp:is_adopted_by |
may be necessary in severe cases
may be necessary for advanced liver disease possible treatment for severe cases |
| gptkbp:is_effective_against |
effective treatment option
|
| gptkbp:is_involved_in |
available for patients
|
| gptkbp:is_monitored_by |
important for detecting relapse
|
| gptkbp:is_popular_in |
approximately 71 million infected worldwide
|
| gptkbp:is_protected_by |
safe sex practices
avoid sharing needles screening blood donations |
| gptkbp:is_tested_for |
HCV antibody test
HCVRNA test Fibro Scan is a non-invasive method used to monitor liver health |
| gptkbp:is_vulnerable_to |
no vaccine available
no effective vaccine available can be variable among individuals |
| gptkbp:metabolism |
used to assess liver damage
|
| gptkbp:population |
includes diverse demographics
|
| gptkbp:provides_information_on |
varies by country
updated regularly by health organizations |
| gptkbp:public_awareness |
important for prevention
increased through campaigns aim to reduce stigma and promote testing |
| gptkbp:receives_funding_from |
increased in recent years
increased for hepatitis research. |
| gptkbp:research |
ongoing for vaccine development
|
| gptkbp:research_focus |
vaccine development
improved treatment options |
| gptkbp:risk_factor |
multiple sexual partners
intravenous drug use blood transfusions before 1992 healthcare exposure increases with chronic infection sharing personal items tattooing with unsterile equipment mother to child transmission |
| gptkbp:scholarships |
available for those affected
available through various organizations available for those undergoing treatment |
| gptkbp:scientific_classification |
gptkb:World_Health_Organization
hepatitis virus |
| gptkbp:screenings |
high-risk populations
for individuals born between 1945 and 1965 for high-risk populations |
| gptkbp:side_effect |
gptkb:fandom
fatigue headache nausea insomnia |
| gptkbp:social_responsibility |
varies by region
blood test affects millions worldwide often asymptomatic may require lifestyle changes HCVRNA test can lead to liver cancer can lead to liver cirrhosis may be asymptomatic anti-HCV antibody test HIV co-infection is common may require lifelong monitoring often requires lifestyle changes studied globally for patterns and trends can resolve spontaneously requires long-term management HIV co-infection common HBV common in HCV patients HIV common in HCV patients |
| gptkbp:symptoms |
fatigue
nausea abdominal pain jaundice loss of appetite can be mild or severe |
| gptkbp:transmission |
blood-to-blood contact
|
| gptkbp:treatment |
antiviral medications
over 95% with direct-acting antivirals can be high in some regions can lead to sustained virologic response required to prevent recurrence critical for successful outcomes improved with early detection and treatment includes direct-acting antivirals includes interferon and ribavirin indicates cure over 95% with modern therapies |